Johns Hopkins tightens rules on industry interaction, bans gifts from drugmakers

14 April 2009

In another move by US academia to cuts its ties with commerce, the Johns Hopkins University Medicine School (JHM) has adopted a new policy  that significantly limits interactions with industry while ensuring  effective, principled and appropriate partnerships with pharmaceutical  and medical device makers. Earlier this month, similar action was  advocated by a group of physicians writing in the Journal of the  American Medical Association (Marketletter  April 13).

Called the Johns Hopkins Medicine Policy on Interaction with Industry,  the policy will take effect July 1. Chief among the new rules are those  that prohibit the acceptance of gifts or entertainment - including food  - regardless of value, from drug and device companies. Consulting  arrangements that carry personal compensation but no real duties also  are prohibited and, beginning in 2010, the JHM will no longer accept  free medicine samples, although in some limited cases, those that are  de-identified (ie, without the brand or manufacturer's name), may be  used for patient education.

Restricts medical reps access

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight